Clear Need

The conventional pharma R&D model is broken, taking many years and $billions for approved medicine with high failure rates in clinic. A new approach is needed.

Clear Solution

We embrace the true complexity of biology. Our network-driven drug discovery ("NDD") approach uses a powerful informatics platform based on sophisticated big data analysis, machine learning and AI.

Clear Plan

We seek collaborations focused on the commercialisation of our NDD platform, creating and licensing NDD discovery programmes as well as out-licensing our own NDD-derived assets.

We are an Oxford, UK-based business with a revolutionary computer-based platform and a unique network-driven drug discovery ("NDD") methodology which allows us to discover novel and better drugs faster.

Who we are

What we do

Read more about our cutting edge in silico techniques, the importance of network science, our strategy and our assets.

What we do

News and Media

View our regulatory announcements, read our publications, see our videos and subscribe to receive email alerts.

News & media

Investors

We are a UK-based company listed (ETX.L) on the Alternative Investment Market (AIM), London Stock Exchange's international market for smaller, growing companies.

Investors

Clear Need

The conventional pharma R&D model is broken, taking many years and $billions for approved medicine with high failure rates in clinic. A new approach is needed.

Clear Solution

We embrace the true complexity of biology. Our network-driven drug discovery ("NDD") approach uses a powerful informatics platform based on sophisticated big data analysis, machine learning and AI.

Clear Plan

We seek collaborations focused on the commercialisation of our NDD platform, creating and licensing NDD discovery programmes as well as out-licensing our own NDD-derived assets.

Share price

Latest Report 2018

Latest news

Research Collaboration Agreement with Novo Nordisk

Partnering & Collaboration